68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用

沈国华 ,  周惠君 ,  邓候富 ,  贾志云

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2015,  39 > 1: (75-79)  
引用本文:
shu
Citation:
shu

68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用

  • 四川大学华西医院核医学科, 成都, 610041

    • 通讯作者: 贾志云, email:shengh1990@126.com
  • 基金项目:

    国家自然科学基金(81171456

    81271532/H1801)

Advances of 68Ga-labelled SSR-targeted peptides (DOTA-TOC,-TATE,-NOC) PET/CT imaging and its preliminary application in neuroendocrine tumors

  • Department of Unclear Medicine, West China Hospitai, Sichuan University, Chengdu 610041, China

    • Corresponding author: Jia Zhiyun, email:shengh1990@126.com

  • 摘要: 近年来,68Ga标记的多肽PET/CT显像为神经内分泌肿瘤(NET)的诊断提供了新的方法和视角。68Ge/68Ga发生器已经商业化,容易获得,并且68Ga标记过程简单方便,显像剂稳定性好。在此基础上,越来越多的研究比较了68Ga标记的多肽PET/CT与传统的形态学显像方法(CT、MRI)及生长抑素受体扫描对NET病灶的诊断效能,发现68Ga标记的多肽PET/CT远远优于后者。此外,68Ga标记的多肽PET/CT显像还能为患者治疗方案的选择、辐射剂量的调整甚至预后效果的评估提供多种重要信息,其有望成为NET患者肿瘤显像的临床首选。笔者就近年来68Ga标记的多肽PET/CT显像在临床上的初步应用研究作一综述。
    Abstract: In recent years, 68Ga-labelled peptides PET/CT has provided a new approach and perspective for the diagnosis of neuroendocrine tumors (NET). 68Ge/68Ga generator has been commercialized, with 68Ga obtained easily. The labeling process is easy, and the 68Ga-labelled peptides are stable.There are an increasing number of reports about the much better diagnostic performance of 68Ga-labelled peptides PET/CT for the detection of NET lesions as compared to traditional morphological imaging procedures (CT, MRI) and somatostatin receptor scintigraphy. In addition, it can offer important clinical information in selecting treatment plan, adjusting the radiation dose and assessing the prognosis. 68Ga-labelled peptides PET/CT is expected to be the standard method and first choice for imaging NET. An overview about the introduction and application of 68Ga-labelled peptides PET/CT in clinical practice is presented.
  • [1] Geijer H,Breimer LH.somatostatin receptor PET/CT in neuroen-docrine tumours:update on systematic review and meta-analysis[J].Eur J Nucl Med Mol Imaging,2013,40(11):1770-1780.
    [2] Rufini V,Calcagni ML,Baum RP.Imaging of neuroendocrine tu-mors[J].Semin Nucl Med,2006,36(3):228-247.
    [3] 王丽华,汪勇先,尹端祉.生长抑素及其类似物的标记技术的发展[J].核技术,2003,26(7):537-544.
    [4] Roosenburg S,Laverman P,Joosten L,et al.PET and SPEC Tima-ging of a radiolabeled minigastrin analogue conjugated with DOTA.NOTA and NODAGA and labeled with 64Cu,68Ga and 111In[J].MolPharm,2014,11(11):3930-3937.
    [5] Decristoforo C,Pickett RD,Verbruggen A.Feasibility and avai-lability of 68Ga-labelled peptides[J].Eur J Nucl Med Mol Imag-ing,2012,39 Suppl 1:S31-40.
    [6] Zhernosekov KP,Filosofov DV,Baum RP,et al.Processing of gen-erator-produced 68Ga for medical application[J].J Nucl Med,2007,48(10):1741-1748.
    [7] Hofmann M,Maecke H,Borner R,et al.Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC:preliminary data[J].Eur J Nucl Med,2001,28(12):1751-1757.
    [8] Giesel FL,Stefanova M,Schwartz LH,et al.Impact of peptide re-ceptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue[J].Q J Nucl Med Mol Imaging,2013,57(2):171-176.
    [9] Boy C,Heusner TA,Poeppel TD,et al.68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue:correlation of sst2 mRNA and SUVmax[J].Eur J Nucl Med Mol Imaging,2011,38(7):1224-1236.
    [10] Gabriel M,Decristoforo C,Kendler D,et al.68Ga-DOTA-Tyr3-oc-treotide PET in neuroendocrine tumors:comparison with somato-statin receptor scintigraphy and CT[J].J Nucl Med,2007,48(4):508-518.
    [11] Mayerhoefer ME,Schuetz M,Magnaldi S,et al.Are contrast media required for 68Ga-DOTATOC PET/CT in patients with neuroen-docrine tumours of the abdomen?[J].Eur Radiol,2012,22(4):938-946.
    [12] Ezziddin S,Lohmar J,Yong-Hing CJ,et al.Does the pretherapeutic tumor SUV in 68Ga DO TATOC PET predict the absorbed dose of 177Lu octreotate?[J].Clin Nucl Med,2012,37(6):e141-e147.
    [13] Kroiss A,Putzer D,Decristoforo C,et al.68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue:differentiation of physio-logical uptake and pathological processes in PET/CT[J].Eur J Nucl Med Mol Imaging,2013,40(4):514-523.
    [14] Naswa N,Sharma P,Kumar R,et al.Usual and unusual neuroen-docrine tumor metastases on 68Ga-DOTANOC PET/CT:a pictorial review[J].Clin Nucl Med,2013,38(6):e239-e245.
    [15] Fanti S,Ambrosini V,Tomassetti P,et al.Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET[J].Biomed Pharmacother,2008,62(10):667-671.
    [16] Ambrosini V,Campana D,Tomassetti P,et al.68Ga-labelled pep-tides for diagnosis of gastroenteropancreatic NET[J].Eur J Nucl Med Mol Imaging,2012,39 Suppl 1:S52-60.
    [17] Haug AR,Cindea-Drimus R,Auernhammer CJ,et al.The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors[J].J Nucl Med,2012,53(11):1686-1692.
    [18] Hofman MS,Kong G,Neels OC,et al.High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours[J].J Med Imaging Radiat Oncol,2012,56(1):40-47.
    [19] Demirci E,Ocak M,Kanasakal L,et al.Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours:preliminary results[J].Nucl Med Commun,2013,34(8):727-732.
    [20] Kabasakal L,Demirci E,Ocak M,et al.Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same pa-tient group with neuroendocrine tumours[J].Eur J Nucl Med Mol Imaging,2012,39(8):1271-1277.
    [21] Velikyan I,Sundin A,Sörensen J,et al.Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE:net uptake rate for accurate quantification[J].J Nucl Med,2014,55(2):204-210.
    [22] Poeppel TD,Binse I,Petersenn S,et al.68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors[J].J Nucl Med,2011,52(12):1864-1870.
    [23] Sandstr MM,Velikyan I,Garske-romn U,et al.Comparative biodis-tribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors[J].J Nucl Med,2013,54(10):1755-1759.
    [24] Ruf J.Cost comparison of In-111-DTPA-octreotide scintigraphy and Ga-68-DOTATOC PET/CT in Germany:two sides of two different coins[J].Eur J Nucl Med Mol Imaging,2012,39(4):723-724.
  • [1] 沈国华 , 周惠君 , 邓候富 , 贾志云 . 68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用. 国际放射医学核医学杂志, 2015, 39(1): 75-79.
    [2] 赵润泽 , 张一帆 . 18F-FDG和68Ga-DOTA-SSA双示踪剂PET/CT在神经内分泌肿瘤中的临床应用. 国际放射医学核医学杂志, 2021, 45(9): 585-590. doi: 10.3760/cma.j.cn121381-202008043-00091
    [3] 汪太松 , 赵晋华 , 宋建华 . PET-MRI和多模式肿瘤显像. 国际放射医学核医学杂志, 2011, 35(5): 261-264. doi: 10.3760/cma.j.issn.1673-4114.2011.05.002
    [4] 倪妙琪 , 吴爽 , 金晨涛 , 田梅 . 68Ga-FAPI PET/CT在恶性肿瘤中的临床应用. 国际放射医学核医学杂志, 2021, 45(5): 307-312. doi: 10.3760/cma.j.cn121381-202102029-00046
    [5] 王冬艳 , 苏成海 . PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展. 国际放射医学核医学杂志, 2011, 35(6): 339-346. doi: 10.3760,cma.j.issn.1673-4114.2011.06.005
    [6] 王彬 , 赵妍 , 陈旸 , 赵新明 . 68Ga-FAPI PET/CT在胃及结直肠肿瘤诊疗中的临床应用进展. 国际放射医学核医学杂志, 2023, 47(1): 39-44. doi: 10.3760/cma.j.cn121381-202205016-00259
    [7] 马晓芳 , 晋建华 . 68Ga-FAPI PET/CT在消化系统恶性肿瘤中的应用研究进展. 国际放射医学核医学杂志, 2023, 47(12): 768-773. doi: 10.3760/cma.j.cn121381-202301003-00374
    [8] 潘永祥 , 王风 , 丁立新 , 杨志 . 68Ga-奥曲肽PET/CT显像患者对周围人群产生的有效剂量的估算. 国际放射医学核医学杂志, 2022, 46(12): 713-717. doi: 10.3760/cma.j.cn121381-202202007-00245
    [9] 张晓瑶 , 方琪 , 王欣璐 . 68Ga-FAPI在疾病诊疗中的应用. 国际放射医学核医学杂志, 2021, 45(7): 449-454. doi: 10.3760/cma.j.cn121381-202006019-00056
    [10] 陈琳 , 邢菲 , 冯悦 , 刘宁 , 秦芝 , 陈跃 . 国产68Ge-68Ga发生器的制备及初步应用评价. 国际放射医学核医学杂志, 2023, 47(8): 484-491. doi: 10.3760/cma.j.cn121381-202210003-00329
    [11] 温健男 , 杨亲亲 , 程超 , 左长京 . 68Ga-PSMA-11 PET/CT代谢体积参数在不同风险分层的初诊前列腺癌患者中的差异研究. 国际放射医学核医学杂志, 2021, 45(12): 741-749. doi: 10.3760/cma.j.cn121381-202009005-00113
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2370
  • HTML全文浏览量:  574
  • PDF下载量:  11
出版历程
  • 收稿日期:  2014-10-28

68Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用

  • 收稿日期: 2014-10-28
基金项目:  国家自然科学基金(8117145681271532/H1801)

摘要: 近年来,68Ga标记的多肽PET/CT显像为神经内分泌肿瘤(NET)的诊断提供了新的方法和视角。68Ge/68Ga发生器已经商业化,容易获得,并且68Ga标记过程简单方便,显像剂稳定性好。在此基础上,越来越多的研究比较了68Ga标记的多肽PET/CT与传统的形态学显像方法(CT、MRI)及生长抑素受体扫描对NET病灶的诊断效能,发现68Ga标记的多肽PET/CT远远优于后者。此外,68Ga标记的多肽PET/CT显像还能为患者治疗方案的选择、辐射剂量的调整甚至预后效果的评估提供多种重要信息,其有望成为NET患者肿瘤显像的临床首选。笔者就近年来68Ga标记的多肽PET/CT显像在临床上的初步应用研究作一综述。

English Abstract

    全文HTML

参考文献 (24)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net